Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploiting the Surfaceome to Develop New Drug Delivery Targets For Atrial Fibrillation

Award Number: F31HL189247
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 03/16/2027
PERIOD OF PERFORMANCE END DATE: 03/15/2028

Group Awards By:

View Award Description

Exploiting the Surfaceome to Develop New Drug Delivery Targets For Atrial Fibrillation - PROJECT SUMMARY Atrial fibrillation (AFib) is the most common heart arrhythmia, affecting more than 10 million US adults each year, and is a major risk factor for stroke and heart failure. Current therapies do not directly target the molecular drivers of atrial remodeling, largely because these pathways are incompletely understood. While several key cell surface glycoproteins and intracellular phosphoproteins involved in calcium handling and excitation-contraction coupling have been implicated in the structural and electrical remodeling that occurs in AFib, region-specific alterations in surface glycoproteins and phosphorylation signaling networks that contribute to AFib remain poorly defined. Thus, a more complete understanding of the molecular pathways that contribute to the initiation and progression of AFib is needed to develop predictive biomarkers and more effective therapies that target underlying disease mechanisms. The proposed studies aim to improve our understanding of AFib-related remodeling by integrating region-specific quantitative surfaceome mapping with intracellular protein and phosphoprotein analyses across four myocardial regions from human hearts. By comparing isolated cardiomyocytes from left and right atria and ventricles from hearts in various stages of heart failure with and without AFib, to healthy hearts, these studies will provide unique insights into chamber- specific alterations in cell surface glycoproteins and signaling pathway activation. Integrating advanced chemoproteomics technologies and bioinformatics with innovative cardiac tissue slice models for assessments of contractility, tissue mechanics, and intracellular calcium handling will provide unique molecular and functional views. Findings will be used to define how dysregulated surface proteins contribute to electrophysiological remodeling and excitation-contraction coupling, providing new opportunities to reveal putative atrial-specific surface proteins that may be targets for future region-specific therapy delivery. Simultaneously, intracellular proteomic and phosphoproteomic analyses will inform how irregular phosphorylation of calcium-handling proteins impacts intracellular calcium cycling to reveal kinase-driven pathways for future therapies. Completing these studies will generate new mechanistic insights into the pathophysiology of AFib, reveal candidate biomarkers for early detection and outcome prediction, and provide a foundation for developing region-specific interventions that have the potential to maximize therapeutic efficacy while minimizing adverse side effects observed with existing therapies. Overall, these studies are designed to provide opportunities for me to learn cutting-edge technologies, advanced bioinformatics, how to integrate molecular and functional data, and key concepts for prioritizing targets for future therapy development, thereby providing a strong foundation for a future career in drug discovery research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = $0 )
2027	2026	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	4215 EMILE ST	OMAHA	NE	68105	DOUGLAS	USA	Cardiovascular Diseases Research	000	1	10/23/2026	NEW	$0
														Subtotal = $0

Issue Date FY: 2026 ( Subtotal = $41,119 )
2026	2026	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	4215 EMILE ST	OMAHA	NE	68105	DOUGLAS	USA	Cardiovascular Diseases Research	000	1	9/17/2026	NEW	$41,119
														Subtotal = $41,119

Grand Total All Awards = $41,119

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploiting the Surfaceome to Develop New Drug Delivery Targets For Atrial Fibrillation

Award Number: F31HL189247

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 03/16/2027

PERIOD OF PERFORMANCE END DATE: 03/15/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer